Insulin inhalation - Alkermes/Eli Lilly and Company
Alternative Names: AIR® insulin; U-500Latest Information Update: 05 Nov 2023
At a glance
- Originator Alkermes
- Developer Alkermes; Eli Lilly and Company
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 07 Mar 2008 Eli Lilly terminates the development and license agreement with Alkermes for the AIR® Inhaled Insulin programme
- 07 Mar 2008 Discontinued - Phase-III for Type-1 diabetes mellitus in World (Inhalation)
- 07 Mar 2008 Discontinued - Phase-III for Type-2 diabetes mellitus in World (Inhalation)